SLC5A5 and hematologic disorder: Recently, the safety and efficacy of VSV-IFN-NIS, an oncolytic VSV incorporating IFN beta and sodium iodine symporter transgenes, was tested in a phase I clinical trial.255 Although a single high-dose intravenous VSV-IFNβ-NIS treatment is safe in heavily pretreated patients with hematologic malignancies, patients still experienced drug adverse events (AEs).